NCT02234869View on ClinicalTrials.gov

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

March 31, 2018

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Interferon Beta

Subcutaneous injection

DRUG

BIIB017 (Peginterferon beta-1a)

Single-use, disposable, prefilled pen for subcutaneous injection

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY